TOPIC

/ company

Jiangsu Hengrui Pharmaceuticals

Jiangsu Hengrui Pharmaceuticals: A leading Chinese pharmaceutical company, headquartered in Lianyungang, Jiangsu, with corporate offices in Shanghai and a global presence including R&D centres in the US and Europe. It specialises in the research, development, manufacturing, and distribution of innovative drugs, primarily focusing on oncology, surgical medicines, cardiovascular, and metabolic diseases. The company is recognised as China’s largest listed pharmaceutical firm and consistently ranks among the top global pharmaceutical companies. Its overall business focus is on innovation, significant R&D investment, and global expansion to address unmet medical needs.

China technology

Chinese biopharma’s global expansion

Chinese developers of innovative drugs are tying up with industry giants to accelerate overseas growth, raise funds and share risks.

30 Sep 2026 - 2:30PM

Biomedicine: Companies

AstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech

29 Sep 2026 - 5:52PM

Biomedicine: Industry Trends

How Chinese biotech is graduating from licensing deals to broader partnerships

26 Sep 2026 - 9:00AM

Hong Kong stock market

China rushes to develop Moderna-style cancer vaccines amid market frenzy

Chinese biotech firms are already working on more than 100 cancer vaccines. Now, many are seeing their shares surge amid Moderna’s breakthrough.

26 Aug 2026 - 12:05PMvideocam

Chinese biotechnology firms are working on more than 100 cancer vaccine programmes, according to analysts. Photo: Shutterstock

China’s private sector

Sugar for the pill: US$8b fund boosts Hong Kong’s biotech hub ambitions

Hong Kong Investment Corporation is stepping up its efforts to position itself amid Beijing’s challenge to US pharmaceutical dominance.

7 Aug 2026 - 6:12PM

Northern Metropolis

John Lee meets business and innovation leaders over Hong Kong’s first 5-year plan

Chief executive meets members of Council of Advisers, including Sun Piaoyang of Jiangsu Hengrui Pharmaceuticals and StarFive Semiconductor Technology CEO Xu Tao.

30 Jul 2026 - 8:56PM

China’s private sector

China’s tycoons rein in charitable donations, switch focus to science, education

One major driver of overall decline in corporate donations has been the prolonged slump in country’s real estate sector.

23 Jul 2026 - 9:00AM

ByteDance founder Zhang Yiming has donated 1.1 billion yuan to projects in his hometown over the past five years. Photo: AFP

China’s private sector

China’s biotech boom: RAS-targeted drugs challenge US dominance

The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.

8 Jul 2026 - 2:00PM

China’s private sector

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

21 Jun 2026 - 9:30AM

China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

7 Jun 2026 - 7:00PM

Chinese pharmaceutical companies may expand into international markets in the coming years. Photo: Shutterstock

US-China trade war

The next tech war? Why biotech may become a new US-China battleground

China’s biotech industry is rapidly moving up the value chain, prompting fears in the US and calls for tighter controls.

2 Jun 2026 - 7:00PMvideocam

Chinese biotech companies have risen up the value chain in recent years, with cross-border licensing deals worth a record US$60 billion in the first quarter of 2026, according to the National Medical Products Administration. Photo: Getty Images

China’s private sector

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

Company’s shares jump in Hong Kong and Shenzhen after tie-up that bolsters China’s growing drug innovation profile.

12 May 2026 - 6:00PM

China’s private sector

How China’s ‘landmark’ drug pricing guidelines could be a boon for biotech

State Council calls for ‘value-based pricing’ for innovative drugs, a move researchers said would benefit private healthcare players.

22 Apr 2026 - 4:15PM

Hong Kong economy

Which global firms are being attracted by Hong Kong’s strategic enterprise scheme?

The South China Morning Post examines 22 firms opening or expanding in the city, with HK$73 billion in investment and 25,000 jobs expected.

21 Apr 2026 - 9:30AM

Pfizer, a leading global research‑based pharmaceutical and biotechnology company, is among the biggest names in the latest cohort. Photo: Reuters

Hong Kong economy

Pfizer, Amgen among 22 majors spreading wings in Hong Kong under investment push

Sixth batch under OASES initiative also features Boehringer Ingelheim, Hengrui and Haya, with Didi and AutoFlight joining transport push.

20 Apr 2026 - 11:56PM

Pfizer is among 22 strategic enterprises planning to open or expand offices in Hong Kong, the SCMP has learned. Photo: Reuters

China’s private sector

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.

26 Mar 2026 - 11:00AM

Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

1 Mar 2026 - 12:00PM

Biomedicine: Industry Trends

China could approve first AI-designed drug next year, Merck executive says

AI and genetics are creating a ‘seismic shift’ in the pharmaceutical business, experts on Asian Financial Forum panel say.

28 Jan 2026 - 6:19PM

AI will allow drug makers to pick better molecules, make better medicines and improve molecule design, Amgen executive says. Photo: Shutterstock

Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

13 Jan 2026 - 7:30AM

Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

8 Jan 2026 - 8:30AM

Science

China’s biopharma sector ‘in prime position to challenge US leadership’

American commission issues stark warning, as analytics firm Clarivate reports that Chinese innovative drug development has entered new phase.

3 Jan 2026 - 7:55AMvideocam

United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

20 Dec 2025 - 8:57AM

US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong

Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

19 Dec 2025 - 8:30AM

China stock market

FTSE’s rebalancing of China indexes to spur US$850 million fund flows: Goldman

Consumer retailers, carmakers and internet companies are expected to bear the brunt of fund outflows.

4 Dec 2025 - 3:01PM

China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

4 Dec 2025 - 10:51AMvideocam

A worker checks the position of a feeding tray in a pharmaceutical manufacturing facility at the Hengrui Biomedical Industrial Park in Lianyungang in Jiangsu province, on December 13, 2021. Photo: Getty Images

New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

11 Dec 2025 - 10:09AM

United States

China’s pharmaceutical sector surges amid growth in sales, licensing income

Strong growth momentum and global push expected to continue, HSBC says.

7 Oct 2025 - 2:18PM

Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

4 Oct 2025 - 10:56AM

Help preserve 120 years of quality journalism.

SUPPORT NOW

Jiangsu Hengrui Pharmaceuticals

Chinese biopharma’s global expansion

Chinese developers of innovative drugs are tying up with industry giants to accelerate overseas growth, raise funds and share risks.

AstraZeneca, Merck, Novo deals inject fresh global momentum into Chinese biotech

How Chinese biotech is graduating from licensing deals to broader partnerships

China rushes to develop Moderna-style cancer vaccines amid market frenzy

Chinese biotech firms are already working on more than 100 cancer vaccines. Now, many are seeing their shares surge amid Moderna’s breakthrough.

Sugar for the pill: US$8b fund boosts Hong Kong’s biotech hub ambitions

Hong Kong Investment Corporation is stepping up its efforts to position itself amid Beijing’s challenge to US pharmaceutical dominance.

John Lee meets business and innovation leaders over Hong Kong’s first 5-year plan

Chief executive meets members of Council of Advisers, including Sun Piaoyang of Jiangsu Hengrui Pharmaceuticals and StarFive Semiconductor Technology CEO Xu Tao.

China’s tycoons rein in charitable donations, switch focus to science, education

One major driver of overall decline in corporate donations has been the prolonged slump in country’s real estate sector.

China’s biotech boom: RAS-targeted drugs challenge US dominance

The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

The next tech war? Why biotech may become a new US-China battleground

China’s biotech industry is rapidly moving up the value chain, prompting fears in the US and calls for tighter controls.

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

Company’s shares jump in Hong Kong and Shenzhen after tie-up that bolsters China’s growing drug innovation profile.

How China’s ‘landmark’ drug pricing guidelines could be a boon for biotech

State Council calls for ‘value-based pricing’ for innovative drugs, a move researchers said would benefit private healthcare players.

Which global firms are being attracted by Hong Kong’s strategic enterprise scheme?

The South China Morning Post examines 22 firms opening or expanding in the city, with HK$73 billion in investment and 25,000 jobs expected.

Pfizer, Amgen among 22 majors spreading wings in Hong Kong under investment push

Sixth batch under OASES initiative also features Boehringer Ingelheim, Hengrui and Haya, with Didi and AutoFlight joining transport push.

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

China could approve first AI-designed drug next year, Merck executive says

AI and genetics are creating a ‘seismic shift’ in the pharmaceutical business, experts on Asian Financial Forum panel say.

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

China’s biopharma sector ‘in prime position to challenge US leadership’

American commission issues stark warning, as analytics firm Clarivate reports that Chinese innovative drug development has entered new phase.

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

FTSE’s rebalancing of China indexes to spur US$850 million fund flows: Goldman

Consumer retailers, carmakers and internet companies are expected to bear the brunt of fund outflows.

.css-1pcrwvc{color:#2aa191;}Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

China’s pharmaceutical sector surges amid growth in sales, licensing income

Strong growth momentum and global push expected to continue, HSBC says.

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

Opinion | How China engineered the rapid rise of its drug innovation industry